Maja Zakošek (Avtor), Sonja Prpar (Avtor), Malan Štrbenc (Avtor), Urban Košak (Avtor), Ilija Ilić (Avtor), Jurij Trontelj (Avtor), Simon Žakelj (Avtor), Stanislav Gobec (Avtor), Darja Pavlin (Avtor), Gregor Majdič (Avtor)

Povzetek

Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi). Seventeen dogs were randomized into two groups (treated with BChEi and untreated) and followed for 6 months at regular check-ups. The dogs’ cognitive status was determined by a Canine Dementia Scale (CADES) questionnaire and two cognitive tests. In dogs with moderate cognitive impairment, treatment caused significant improvement in the clinical rating of cognitive abilities and the performance-based tests of cognitive functioning when compared to the untreated group (p < 0.001). Dogs treated with BChEi showed markedly improved cognitive function with enhanced quality of life. No side effects were observed in the treated dogs with moderate cognitive impairment. According to the results of this preliminary study, there is an indication that novel BChEi may be a promising drug for the treatment of CCD in dogs and may be an interesting candidate for the treatment of Alzheimer's disease in humans. However, further clinical studies are needed to confirm this.

Ključne besede

Alzheimer’s disease;butyrylcholinesterase;butyrylcholinesterase inhibitor;canine cognitive dysfunction;canine dementia scale;dogs;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.01 - Izvirni znanstveni članek
Organizacija: UL VF - Veterinarska fakulteta
UDK: 636.09:616
COBISS: 77000195 Povezava se bo odprla v novem oknu
ISSN: 2045-2322
Št. ogledov: 226
Št. prenosov: 62
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarne ključne besede: Cognitive Dysfunction;Butyrylcholinesterase;Dogs;
Vrsta dela (COBISS): Članek v reviji
Strani: str. [1-10]
Letnik: art. 18098
Zvezek: ǂVol. ǂ11
Čas izdaje: 2021
DOI: 10.1038/s41598-021-97404-2
ID: 13534217
Priporočena dela:
, ni podatka o podnaslovu
, two facets of the same disease?
, optimization of a butyrylcholinesterase inhibitor series
, unraveling the mystery
, ni podatka o podnaslovu